



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,459	07/27/2009	Cheng Liu	21601.0006(27527/40666)	7677
4743	7590	08/09/2011	EXAMINER	
MARSHALL, GERSTEIN & BORUN LLP			SPECTOR, LORRAINE	
233 SOUTH WACKER DRIVE				
6300 WILLIS TOWER			ART UNIT	PAPER NUMBER
CHICAGO, IL 60606-6357			1647	
			NOTIFICATION DATE	DELIVERY MODE
			08/09/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mgbdocket@marshallip.com



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/585,459	27 July, 2009	LIU ET AL.	21601.0006(27527/40666)

COUNSEL/ORGANIZATION		EXAMINER	
		ART UNIT	PAPER
MARSHALL, GERSTEIN & BORUN LLP 233 SOUTH WACKER DRIVE 6300 WILLIS TOWER CHICAGO, IL 60606-6357		1647	20110803

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 6/2/11 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): With respect to group a), applicants were required to "elect a single antibody including disclosure of the full heavy and light chains, and any and all SEQ ID NOs: that correspond to the elected antibody. If the SEQ ID NOs: of claim 20 pertain to a single antibody, then applicants must elect a single SEQ ID NO: to be prosecuted. If those SEQ ID NOs: correspond to multiple different antibodies, then that/those sequences that correspond to the elected antibody must be identified, and an election of one must be made. Similarly, a single sequence from those listed in each of claims 33 and 39 must be elected, consistent with the election of a single antibody."

In response, applicants have elected the antibody comprising the light and heavy chain amino acid sequences of SEQ ID NO: 43 and 53. However, applicants have not stated to which antibody (RX1, 5H4, MC1 or MC3) those sequences correspond, nor have applicants disclosed which of the CDRs of SEQ ID NO: 1-6 and 10-38 are comprised in SEQ ID NO: 43 and 53. When identifying the CDR sequences, applicants are required to identify which sequence corresponds to which CDR of the elected antibody. Finally, applicants have neglected to point out which sequences of claims 33 and 39 correspond to the specifically elected antibody.

See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

/Lorraine Spector/
Primary Examiner, Art Unit 1647